BMJ Hosted (Intended for Healthcare Professionals) | BMJ

Click on the panels below to find out more about our latest hosted content

Rosacea: Beyond the visible report
A survey of 710 people with rosacea and 554 doctors has revealed valuable insights on the invisible impact of a visible disease for the patients and the community. It is time to fight back against stereotypes and talk openly about rosacea burden.
Dermatology
Visit Microsite
The Acne Burden Surveys
Dermatology
Visit Microsite
Galapagos-sponsored Symposia and Meet-the-Expert sessions at ECCO 2021

Code: GL-IBD-NA-202105-00016
Date of Preparation: May 2021
Learn more about Galapagos, and our sponsored activities during ECCO.
Intended for Healthcare professionals. This programme is not affiliated with ECCO.
Code: GL-IBD-NA-202105-00016 Date of Preparation: May 2021
Gastroenterology
Visit Microsite
Olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Olumiant may be used as monotherapy or in combination with methotrexate.

Olumiant® and Lilly are registered trademarks of Eli Lilly and Company.
©2021 Eli Lilly and Company. All rights reserved.
Click here for prescribing information and adverse events reporting. This content is promotional and has been developed, organised and funded by Lilly.Intended for UK healthcare professionals only.
PP-BA-GB-1049 September 2021
Rheumatology
Visit Microsite
Bench to Bedside OnDemand:
The Growing (Anti)body of Evidence for the Treatment of Mild-to-Moderate COVID-19
COVID-19
Visit Microsite